Information  X 
Enter a valid email address

Zoetic Interntnl PLC (ZOE)

  Print      Mail a friend

Tuesday 30 June, 2020

Zoetic Interntnl PLC

Total Voting Rights & Reporting Extension

RNS Number : 6023R
Zoetic International PLC
30 June 2020
 

 

Zoetic International plc

("Zoetic" or the "Company")

30 June 2020

Total Voting Rights

 

Reporting Extension

 

Total voting rights

 

Following the admission to trading of new ordinary shares of 1 pence each ("Ordinary Shares") on 17 June 2020, the Company has 194,570,034 Ordinary Shares in issue, each with one voting right.  There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares and voting rights is 194,570,034 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Reporting Extension - Covid-19 Pandemic

 

In accordance with the Financial Conduct Authority's guidance published on 26 March 2020 regarding the extension of reporting full year results for listed companies subject to Chapter 4 of the Disclosure Guidance and Transparency Rules from 4 months to 6 months, the Company will publish its audited results for the year to 31 March 2020 by 30 September 2020.

 

 

**ENDS**

 

Enquiries

 

Zoetic International plc   c/o IFC Advisory

Trevor Taylor, Co-CEO

 

Allenby Capital Limited (Financial Adviser and Broker)                                              +44 (0) 20 3328 5656

Nick Harriss

Nick Naylor

 

IFC Advisory Ltd (Financial PR and IR)                                                                             +44 (0) 20 3934 6630

Tim Metcalfe

Graham Herring

Florence Chandler


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVRURRNRRBUNOAR

a d v e r t i s e m e n t